(Q34732986)

English

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis (English)

1 reference

Europe PubMed Central

4 August 2017

gram-positive bacteria

0 references

0 references

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

Bacteroides fragilis

object named as

Bacteroides fragilis

1 reference

based on heuristic

inferred from title

author name string

Girard AE

1

1 reference

Europe PubMed Central

4 August 2017

Girard D

2

1 reference

Europe PubMed Central

4 August 2017

Gootz TD

3

1 reference

Europe PubMed Central

4 August 2017

Faiella JA

4

1 reference

Europe PubMed Central

4 August 2017

Cimochowski CR

5

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

1 October 1995

1 reference

Europe PubMed Central

4 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

4 August 2017

39

1 reference

Europe PubMed Central

4 August 2017

2210-2216

1 reference

Europe PubMed Central

4 August 2017

10

1 reference

Europe PubMed Central

4 August 2017

In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Drug therapy. Clinical Pharmacokinetics (first of two parts).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

Laboratory evaluation of 3-(5-tetrazolyl) penam, a new semisynthetic beta-lactam antibacterial agent with extended broad-spectrum activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

7 July 2018

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

26 October 2018

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

26 October 2018

Lung tissue concentrations of cefoperazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

26 October 2018

Inappropriate use of oral ciprofloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162916

26 October 2018

Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin

1 reference

https://pubmed.ncbi.nlm.nih.gov/8619569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/8619569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices

1 reference

https://pubmed.ncbi.nlm.nih.gov/8619569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative efficacy of ceftriaxone in experimental infections involving Bacteroides fragilis and Escherichia coli

1 reference

https://pubmed.ncbi.nlm.nih.gov/8619569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ciprofloxacin: an overview and prospective appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/8619569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.39.10.2210

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34732986&oldid=1630118683"